{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T19:43:39Z","timestamp":1767642219433,"version":"3.48.0"},"reference-count":24,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>Glycogen storage disease type Ib (GSD Ib) is a rare hereditary glycogen disorder that results in inadequate maintenance of glucose homeostasis, accumulation of glycogen in different organs, loss and dysfunction of neutrophils. Crohn\u2019s-like disease is observed in up to 24\u201377% of GDS Ib cases. Recently, empagliflozin has been recommended as a treatment for neutrophil dysfunction in GDS Ib patients with or without Crohn\u2019s-like disease. There are no guidelines for the treatment of inflammatory bowel disease (IBD) manifestation in GSD Ib patients, although some cases have been treated with granulocyte colony-stimulating factor and others with IBD conventional therapy, resulting in partial IBD remission. Herein, we describe a child with GDS Ib and Crohn\u2019s-like disease who was treated with empagliflozin and achieved complete remission after 2\u2009years of treatment. This case is the first one with such a long follow-up evaluation including endoscopic and magnetic resonance enterography assessment. Our clinical evidence of remission of IBD manifestation in our GSD Ib patient and the role of neutrophils in GDS Ib described in the literature suggest a strong association with IBD pathophysiology and neutrophil function. The use of empagliflozin resulted in significant improvements in gastrointestinal symptoms, reduced drug usage, and enhanced quality of life in the patient, with a favorable safety profile, offering a promising new therapeutic option for this population.<\/jats:p>","DOI":"10.1177\/17562848231202138","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T07:52:38Z","timestamp":1695887558000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Crohn-like disease long remission in a pediatric patient with glycogen storage disease type Ib treated with empagliflozin: a case report"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4851-9795","authenticated-orcid":false,"given":"Margherita","family":"Calia","sequence":"first","affiliation":[{"name":"Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Mario Luciano","family":"Arosio","sequence":"additional","affiliation":[{"name":"Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viola","family":"Crescitelli","sequence":"additional","affiliation":[{"name":"Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Fornari","sequence":"additional","affiliation":[{"name":"Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Pretese","sequence":"additional","affiliation":[{"name":"Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Gasperini","sequence":"additional","affiliation":[{"name":"Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Zuin","sequence":"additional","affiliation":[{"name":"Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Via G. B. Pergolesi, 33, 20900 Monza (MB), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-27"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000474"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.3233\/TRD-160006"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2019.103767"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1816143116"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004465"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-021-01100-w"},{"key":"e_1_3_5_9_2","first-page":"309","article-title":"Untargeted metabolomic profiling in a patient with glycogen storage disease Ib receiving empagliflozin treatment","volume":"63","author":"Tallis E","year":"2022","unstructured":"Tallis E, Karsenty CL, Grimes AB, et al. Untargeted metabolomic profiling in a patient with glycogen storage disease Ib receiving empagliflozin treatment. JIMD Rep 2022; 63: 309\u2013315.","journal-title":"JIMD Rep"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/ped.14629"},{"key":"e_1_3_5_11_2","article-title":"Repurposing of empagliflozin as a possible treatment for neutropenia and inflammatory bowel disease in glycogen storage disease Type Ib: a case report","volume":"14","author":"Makrilakis K","year":"2022","unstructured":"Makrilakis K, Barmpagianni A, Veiga-da-Cunha M. Repurposing of empagliflozin as a possible treatment for neutropenia and inflammatory bowel disease in glycogen storage disease Type Ib: a case report. Cureus. 2022; 14: e27264.","journal-title":"Cureus"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.7453\/gahmj.2013.008"},{"key":"e_1_3_5_13_2","unstructured":"WHO. WHO child growth standards: length\/height-for-age weight-for-age weight-for-length weight-for-height and body mass index-for-age: methods and development https:\/\/www.who.int\/publications-detail-redirect\/924154693X (2006)."},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.280777"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003046"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.649"},{"key":"e_1_3_5_17_2","unstructured":"Morgan MA. Radiopaedia. Spleen size (pediatric) | Radiology Reference Article | Radiopaedia.org https:\/\/radiopaedia.org\/articles\/spleen-size-paediatric (accessed 14 June 2022)."},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22706"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2000.105232"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v9.i19.5280"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v9.i16.4081"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200105000-00008"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01503-8"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.11.014"},{"key":"e_1_3_5_25_2","first-page":"252","article-title":"Patient-reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: an international questionnaire study","volume":"64","author":"Gr\u00fcnert SC","year":"2023","unstructured":"Gr\u00fcnert SC, Venema A, LaFreniere J, et al. Patient-reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: an international questionnaire study. JIMD Rep 2023; 64: 252\u2013258.","journal-title":"JIMD Rep"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848231202138","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848231202138","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848231202138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:26:41Z","timestamp":1767630401000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848231202138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":24,"alternative-id":["10.1177\/17562848231202138"],"URL":"https:\/\/doi.org\/10.1177\/17562848231202138","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"type":"print","value":"1756-2848"},{"type":"electronic","value":"1756-2848"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"17562848231202138"}}